Junshi Biosciences of Shanghai stopped a China Phase III trial of its PD-1 checkpoint inhibitor early because it was effective in patients with nasopharyngeal carcinoma (NPC). Tuoyi (toripalimab) met its primary endpoint of improvement in progression free survival. It was administered in combination with gemcitabine/cisplatin as a first-line treatment in patients with recurrent or metastatic forms of the disease. In 2018, Tuoyi was originally approved in China as a second-line treatment of metastatic melanoma. More details.... Stock Symbol: (HK: 1877; SHA: 688180) Share this with colleagues: // //